CAS: 4584-46-7; 2-Dimethylaminoethyl Chloride Hydrochloride

上下游产品

CAS号108-01-0 2-(二甲基氨基)乙醇 | CAS号124-40-3 二甲胺 | CAS号107-07-3 2-氯乙醇 | CAS号106823-66-9 N,N-dimethyl-2-... | CAS号1072-11-3 Ethanamine,2,2'... | CAS号42399-41-7 地尔硫卓 | CAS号14087-57-1 1,1-dichloro-N-... | CAS号486-16-8 卡比沙明 | CAS号51344-13-9 N-[2-(4-硝基苯氧基)乙... | CAS号221915-84-0 2-(3-溴苯氧基)-N,N-二甲基乙胺 | CAS号18833-74-4 dimethyl-[2-(7,... | CAS号18167-29-8 2-[2-(二甲基氨基)乙氧基... | CAS号22291-83-4 3-[2-(dimethyla...

N,N-二甲基乙醇胺置于氯化亚砜体系中,用 乙醚 作为反应溶剂,化学反应生成 二甲氨基氯乙烷盐酸
参考文献:通过应变促进的环辛炔-叠氮化物环加成反应,在s180细胞膜上用99Mtc放射性标记胆碱磷脂的两步策略.
标题:通过应变促进的环辛炔-叠氮化物环加成反应,在s180细胞膜上用99Mtc放射性标记胆碱磷脂的两步策略.
摘要:作为肿瘤标志物,用99Mtc放射性标记细胞膜中含胆碱(cho)的磷脂是一项挑战.通过大的配体将金属放射性核素与cho结合的常规策略会破坏cho的生物活性,从而导致较低的肿瘤与非肿瘤比率.基于应变促进的环辛炔-叠氮化物环加成(spaac)反应的预靶向策略被用来解决这个普遍的问题.合成功能性点击合成子作为预靶向成分:叠氮基乙基胆碱(aecho)作为肿瘤标记物,氮杂二苯并环辛炔(adibo)与双(2-Pieolyl)胺(bpa)配体(adibo-Bpa)共轭,标记为99Mtc(co)3-和叠氮基结合基团.体外细胞实验和体内生物分布实验均表明,通过这种两步预靶向策略,它可在细胞膜中放射性标记cho.我们认为,这种预靶向策略确实可以增强靶标特异性,并减少背景信号以优化成像质量.
DOI:10.1016/j.Bmcl.2016.10.026

专利信息

专利号:US-7576234-B2
优先权日:2002-05-15
标题 :Synthesis of 2-alkyl amino acids
发明人：CHORGHADE MUKUND S; GURJAR MUKUND K; MOHAPATRA DEBENDRA K
权利人:GENZYME CORP
摘要:Non-natural amino acids such as 2-alkylated amino acids allow for the synthesis of a wider variety of peptidal and non-peptidal pharmaceutically active agents. A method of preparing a 2-alkyl amino acid involves a Michael-type addition of a nucleophile to a dialkyl 2-methylidenylpropan-1,3-dioate and the conversion of a ester moiety into an amino moiety. The present invention also discloses a method of preparing a class of iron chelating agents related to desferrithiocin, all of which contain a thiazoline ring. In this method, an aryl nitrile or imidate is condensed with cysteine, a 2-alkyl cysteine, or a cysteine ester.

专利号:US-2022356139-A1
优先权日:2019-09-03
标 题:Synthesis of deuterated aldehydes
发明人：WANG WEI
权利人:ARIZONA BOARD OF REGENTS ON BEHALF OF ATHE UNIV OF ARIZONA
摘要:Described are methods for preparing a deuterated aldehyde using N-heterocyclic carbene catalysts in a solvent comprising D 2 O. The methods may be used to convert a wide variety of aldehydes (e.g., aryl, alkyl, or alkenyl aldehydes) to C-1 deuterated aldehydes under mild reaction conditions without functionality manipulation.

专利号:WO-2023112055-A1
优先权日:2021-12-15
标 题 :New synthetic process design for the synthesis of carboxy tormifene and purity analysis to strengthen antidoping testing
发明人：KUMAR GANGASANI JAGADEESH; PAWAR SACHIN DATTRAM; RADHAKRISHNANAND PULLAPANTHULA; MURTY UPADHYAYULA SURYANARAYANA; SAHU PURAN LAL; DUBEY SACHIN; SAHU KAPENDRA; UPADHYAY AWANISH; KUMAR PRAMOD
权利人:DIRECTOR NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RES GUWAHATI NIPER G; DIRECTOR NAT DOPE TESTING LABORATORY NDTL
摘要:The present invention relates to a process for preparing a compound of formula I: I. The compound of formula I is useful in anti-doping tests.

专利号:US-3959322-A
优先权日:1960-09-22
标 题:Synthesis of 13-alkyl-gon-4-ones
发明人：HUGHES GORDON ALAN; SMITH HERCHEL
权利人:SMITH HERCHEL
摘要:The preparation of 13-methylgon-4-enes and novel 13-polycarbonalkylgon-4-enes by a new total synthesis is described. 13-Alkylgon-4-enes having progestational, anabolic and androgenic activities are prepared by forming a tetracylic gonane structure unsaturated in the 1,3,5(10),9(11) and 14-positions, selectively reducing in the B- and C-rings, and converting the aromatic A-ring compounds so-produced to gon-4-enes by Birch reduction and hydrolysis.

专利号:US-5527824-A
优先权日:1985-07-22
标题 :Substituted Di-T-Butlyphenols useful for inhibiting leukotriene synthesis
发明人：SCHERRER ROBERT A
权利人:RIKER LABORATORIES INC
摘要:Substituted Di-T-Butylphenols useful for inhibiting the synthesis of leukotrienes are disclosed.

专利号:US-11512097-B2
优先权日:2019-11-25
标题 :Heterocyclic compounds as Delta-5 desaturase inhibitors and methods of use
发明人：ALLEN JENNIFER R; BELTRANI MICHELA; BOURBEAU MATTHEW P; DAMYANOVA TEODORA P; LINGARD IAIN; MINATTI ANA E; VINCETTI PAOLO
权利人:AMGEN INC
摘要:The present disclosure provides compounds useful for the inhibition of Delta-5 Desaturase (“D5Dâ€?). The compounds have a general Formula I n nwherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a metabolic or cardiovascular disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.